141 Platelet aggregation capability in children with cystic fibrosis  by Simonova, O. et al.
Posters 8. Pulmonology S83
141 Platelet aggregation capability in children with cystic ﬁbrosis
O. Simonova1, O. Gordeeva1, Y. Gorinova1, V. Botvinyeva1. 1Scientiﬁc Center of
Children’s Health, RAMS, Moscow, Russian Federation
Objectives: To determine platelet aggregation capability for various variants of
antigene system AB0 in patients with cystic ﬁbrosis (CF).
Methods: 55 CF children (homozygous and heterozygous on F508 del mutation)
were enrolled. 46% girls and 54% boys had mild form of CF, 54% girls and 46%
boys had severe form. We investigated the function of platelet aggregation with:
thrombin, adenosinediphosphate (ADP) and arachidonic acid (AA).
Results: Patients with severe form of CF most frequently (29%) had 0 (I); B (III)
have not been revealed in this group, meanwhile 22.2% patients with mild form of
CF had A (II) and AB (IV) have been revealed. Platelet aggregation with ADP has
signiﬁcant differences between blood groups A (II) and 0 (I), (p = 0.019). Values
were ranged 2.5–97.5 percentile in patients with 0 (I) and 2.5−25 percentile in A
(II). Data of aggregation with AA did not show signiﬁcant differences between
groups.
Signiﬁcant difference between homozygous F508 del and heterozygous F508 del
patients was shown in aggregation with trombin (p = 0.03). There is a tendency
to hyperaggregation in heterozygous patients meanwhile homozygous had both hy-
poaggregation and hyperaggregation. Difference on other tests between homozygous
and heterozygous patients is not signiﬁcant.
Conclusion: First results of this study should be interpreted according to system
ABO, severity of disease and genotype in patients with CF. These aspects play an
important role for individual treatment.
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Objectives: European guidelines for immunization in Cystic Fibrosis (CF) children
have been published in 2005. However, no survey of immunization in this population
has been reported yet.
Methods:We performed a survey to analyze immunization coverage and timeliness
of vaccines in children with CF. Data were extracted from a study which aimed
to analyze H1N1 inﬂuenza pandemy in 439 patients with CF followed in the CF
referral centers of the Paris metropolitan area.
Results: 134 children aged between 9 months and 17.5 years were enrolled in the
study. 43% of children had at least one F508del mutation. 83% of the children
had been vaccinated with BCG. Coverage for diphtheria–tetanus–pertussis (DTP),
polio (Pol) and Haemophilus (Hi) approximated 100% at 24 months but decreased
to 57% at 14 years. 85% of the children had had Measles–Mumps–Rubella (MMR)
vaccine at 18 months. Hepatitis A and B vaccination coverage at 24 months was
poor (respectively 15% and 50% of the children). Hepatitis B coverage did not
improve with age (55.2% at 14 years). Only 50% of the children had completed
a full pneumococcal vaccination schedule. Immunization coverage for seasonal ﬂu
was 72% the year of the study. Very few children were immunized for varicella
and conjugate meningococcal C (13% for both), papillomavirus vaccine and 11
rotavirus vaccine (less than 1%).
Conclusion: Immunization coverage was satisfactory for DTP, Pol, Hi and MMR.
Children with CF should be strictly monitored for vaccinations for hepatitis A and B,
pneumococcus and seasonal ﬂu.
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Objectives: Early infection with Pseudomonas aeruginosa has been associated to
higher morbidity and mortality in patients with Cystic Fibrosis. A better knowledge
of the factors that are involved in its early infection can be useful to prevent its
acquisition.
Methods: Retrospective study in children diagnosed with Cystic Fibrosis. We have
analysed demographic variables, genotypes and positive cultures to P. aeruginosa,
and considered as winter from January to March, spring from April to June, summer
from July to September and autumn from October to December. We practiced
at least 4 cultures per year to each patient.
Results: We evaluated 95 children. From them, 54 (56.8%) had at least 1 positive
culture to P. aeruginosa and 35 (36.8%) also had a second positive one. The mean
age for the ﬁrst positive culture was 24 months (2−86 months). 9 of the patients
developed the positivity during the winter time (16.66%), 14 during the spring
(25.9%), 17 in summer (31.5%) and 14 in autumn (25.9%). 35 children had a
second positive culture with a mean age of 47.5 months (8–153 months). The
second isolation was observed in winter in 5 children (14.3%), in spring in 10
children (26.8%), in summer in 8 children (22.8%) and in autumn in 12 children
(34.3%).
Conclusion: Both ﬁrst and second isolation of P. aeruginosa are less frequent in
winter, being more prevailing in summer and autumn months. This suggests that
seasonality as a factor that contributes to its acquisition.
The identiﬁcation of factors that take part in its acquisition such as seasonality,
could help us to implement recommendations to prevent this infection.
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Colonization by Pseudomonas aeruginosa (PA), the most prevalent organism
isolated from CF patients’ sputum is associated with an accelerated clinical and
functional deterioration and is an important predictor of mortality.
Aim: To assess the clinical and functional differences between CF patients colonized
by PA and other CF patients with distinct bronchial colonization.
Methods: Retrospective analysis of the adult CF patients followed at our specialized
CF centre, between 2008−12. Clinical ﬁles were reviewed in order to collect
the following data: demographics, genotype, sputum colonization, lung function
(FEV1), nutritional status (BMI). Bronchial colonization was deﬁned according to
the Leeds criteria. Patients submitted to lung transplant or with irregular follow-up
were excluded. Statistical analysis was done with SPSS 20. The level of statistical
signiﬁcance considered was 0.05.
Results: We included 34 patients in this study, 54% were females, median age
30.8±8.5 years. del508F was the most common mutation found (25% homozygous).
Colonization by PA was found in 68%, S. aureus in 65% (36% MRSA), B. cepacea
in 9% and fungus in 47%. We found positive correlations between: female gender
and MRSA colonization; colonization by PA and fungus. No correlation was found
between: bronchial colonization and BMI. We estimated Kaplan–Meier survival
curves using FEV1 as a surrogate marker, then we applied the log rank test and
found that mucoid PA colonized (p = 0.043) patients had a faster FEV1 decline.
Conclusion: We concluded that colonization by mucoid PA has a great impact
on disease severity, has seen by a faster FEV1 decline and consequently adding
mortality risk.
